L-Plat

SUSPENDED · PHASE3 · Metastatic Colorectal Cancer

Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line setting.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.